Chhaya is a seasoned biopharmaceutical executive with over 20 years of experience driving drug development from Phase 1 through global regulatory approvals and commercial launches. She is passionate about developing therapies to meet critical patient needs, having led diverse functions across Clinical Supply Chain, CMC, Quality, Regulatory, Pharmacovigilance, Medical Affairs, IT, and HR in both small and mid-sized biotech and pharma companies.



Before joining Praesidia, Chhaya was SVP and Chief Business Officer at Radius Health, where she played a pivotal role in the approval and launch of Elacestrant—the first oral SERD—which achieved $275M in first-year sales and is projected to exceed $1B. She also led R&D and Discovery for their osteoporosis portfolio, securing approvals in the EU, Japan, and expanded US labels, generating over $250M annually.



Earlier in her career, Chhaya spent 12 years at Shire Pharmaceuticals, ultimately serving as VP of Product Strategy in Technical Operations, overseeing strategic planning for a $5B portfolio and contributing to three successful acquisitions.



Chhaya holds a B.S. in Engineering, is a certified quality engineer and manager, and earned advanced leadership credentials from Wharton.